Molecular Sciences, Astex Pharmaceuticals and Department of Biochemistry, NKI (Netherlands Cancer Institute), Amsterdam
Deubiquitinating enzymes (DUBs) are associated with numerous cellular signalling pathways and are implicated in the pathology of diseases such as cancer and neurological disorders. Current DUB-targeted inhibitors have limited potencies and specificities. In my postdoc, I am investigating the mechanism of action of competitive and allosteric DUB inhibitors. I am employing a combination of biophysical, biochemical and structure-based drug discovery approaches to generate specific, high-affinity inhibitors against DUBs which might further find therapeutic applications in neurodegenerative disorders and cancer.